Browsing Tag
Memorises Bio
2 posts
Ipsen agrees €700m Memo Therapeutics deal as acquisition spree accelerates
Ipsen agrees a €700 million Memo Therapeutics deal days after Kartos. Read how the acquisitions reshape its rare-disease pipeline and cash strategy now.
Can potravitug justify Ipsen’s €700m-plus Memo Therapeutics acquisition?
Ipsen is acquiring Memo Therapeutics to secure potravitug, a clinical-stage antibody targeting a serious kidney transplant complication. The structure limits Ipsen’s upfront exposure while placing the larger valuation behind clinical, regulatory and commercial success.